Alzamend Neuro reported financial results for Q1 fiscal 2025 ended July 31, 2024. Net loss narrowed to $974,411 from $3,527,766 in Q1 2024. Research and development expenses decreased 91% to $206,571, while general and administrative expenses fell 35% to $755,834. The company had no revenue in either period.Cash and cash equivalents increased to $1.2 million as of July 31, 2024, compared to $376,048 as of April 30, 2024. During Q1, Alzamend raised $2.5 million through the sale of Series A Convertible Preferred Stock. The company also entered agreements to potentially raise up to $25 million in additional funding.Alzamend continues to advance its lead candidates AL001 and ALZN002 for Alzheimer's disease and other indications. The company plans to initiate new clinical trials for AL001 in 2025 and is seeking a new contract research organization for ALZN002 trials after its previous CRO terminated their agreement in February 2024.

Alzamend Neuro reported financial results for Q1 fiscal 2025 ended July 31, 2024. Net loss narrowed to $974,411 from $3,527,766 in Q1 2024. Research and development expenses decreased 91% to $206,571, while general and administrative expenses fell 35% to $755,834. The company had no revenue in either period.Cash and cash equivalents increased to $1.2 million as of July 31, 2024, compared to $376,048 as of April 30, 2024. During Q1, Alzamend raised $2.5 million through the sale of Series A Convertible Preferred Stock. The company also entered agreements to potentially raise up to $25 million in additional funding.Alzamend continues to advance its lead candidates AL001 and ALZN002 for Alzheimer's disease and other indications. The company plans to initiate new clinical trials for AL001 in 2025 and is seeking a new contract research organization for ALZN002 trials after its previous CRO terminated their agreement in February 2024.